Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Jul 6.

Published in final edited form as: Vaccine. 2012 May 23;30(32):4849–4858. doi: 10.1016/j.vaccine.2012.05.006

Table I.

Antibodies used in this study.

Antibody	Isotype	Reference	Immunogen	Epitope Specificity	Protection
1. Anti-CPS type III antibodies
S9	IgM	[14]	GBS	complete CPS_III	in vivo
S3.1A6	IgG1	[35]	Tet-CPS_III	complete CPS_III 3-D epitope	in vitro^a
S3.2A6	IgG1	[35]	Tet-CPS_III	complete CPS_III 3-D epitope	in vitro^a
S3.1B1	IgG2a	[35]	Tet-CPS_III	complete CPS_III 3-D epitope	in vitro^a
SB3	IgM	[17]	GBS	non-sialylated CPS_III	no^b
SF23	IgG3	[17]	GBS	non-sialylated CPS_III	no
SS8	IgG2a	[17]	GBS	complete CPS_III	in vivo
SV18	IgM	[17]	GBS	complete CPS_III	in vivo
SE11	IgM	[17]	GBS	non-sialylated CPS_III	no
2. Anti-ganglioside Abs, non CPS_III Abs binding GBS, and control Abs
B6.1	IgM	[52]	C. albicans	Isotype control	NT^c
L2-I5	IgG3	[53]	C. trachomatis	Isotype control	NT
S3	IgM	[14]	GBS	GBS group carbohydrate	No
S7	IgM	[14]	GBS	GBS group carbohydrate	No
A2B5	IgM	[29]	chick retina cells	GT3 and 0-acetyl GT3 ganglioside	NT
Mel-1 (clone R24)	IgG3	[26]	melanoma cells	GD3 ganglioside	NT
anti-CD60b (clone JONES)	IgM	[27]	retinal cells	9-0-acetyl GD3	NT
MB3.6	IgG3	[28]	melanoma cells	disialo GD3 ganglioside	NT

^a

These Abs opsonize live GBS for ingestion and killing by PMNs; unpublished data from H.J. Jennings, et al.

^b

Unpublished data, D. Pritchard, M. Egan.

^c

Not tested